TNFRSF10B and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting CD25 as well as TRAILR2 or DR5 resulted in substantial cytotoxicity against leukemic cell lines and leukemic cells derived from AML, ALL, CML and CLL patient samples.